Related Experiment Video
Updated: Apr 19, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells
Tomasz Wojcik1, Elzbieta Buczek1, Katarzyna Majzner2
1Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Bobrzynskiego 14, 30-348 Krakow, Poland.
Abstract:
Although anthracycline antibiotics have been successfully used for nearly half a century in the treatment of various malignancies, their use is limited by their cardiac and vascular toxicities, and the mechanisms of these toxicities are still not entirely clear. Herein, we comprehensively characterized cytotoxic effects of two structurally related anthracyclines, doxorubicin and daunorubicin. In nanomolar concentrations, both drugs induced DNA damage and increased nuclear area that were associated with their accumulation in the nucleus (doxorubicin ⩾50 nM and daunorubicin ⩾25 nM) as evidence by Raman microspectroscopy at 3820-4245 cm(-1). At low micromolar concentrations, doxorubicin (⩾5 μM) and daunorubicin (⩾1 μM) increased the generation of reactive oxygen species, decreased intracellular reduced glutathione, induced an alteration in endothelial elasticity and caused a reorganization of the F-actin cytoskeleton. In isolated mouse aortic rings, doxorubicin (⩾50 μM) was less potent than daunorubicin (⩾5 μM) in impairing the endothelium-dependent response. In summary, using a comprehensive endothelial profiling approach, we demonstrated clear-cut differences in the potencies to induce endotheliotoxic responses for two structurally similar chemotherapeutics, at a nuclear, cytosolic and membrane levels. Furthermore, our results suggest that the differences in the endothelial toxicities of doxorubicin and daunorubicin are linked to differences in their nuclear accumulation and the DNA damage-triggered response of the endothelium.
Insights
Doxorubicin and daunorubicin, used in cancer treatment, show distinct toxic effects on blood vessels. Differences in nuclear accumulation and DNA damage response explain their varying endotheliotoxicity, impacting treatment strategies.
Area of Science:
- Cardiovascular Pharmacology
- Cancer Therapeutics
- Cellular Toxicology
Background:
- Anthracycline antibiotics like doxorubicin and daunorubicin are vital cancer treatments.
- Their clinical use is restricted by cardiac and vascular toxicities with unclear mechanisms.
Purpose of the Study:
- To comprehensively characterize and compare the cytotoxic effects of doxorubicin and daunorubicin.
- To elucidate the distinct mechanisms underlying their endotheliotoxicity.
Main Methods:
- Raman microspectroscopy to assess drug accumulation and DNA damage.
- Evaluation of reactive oxygen species (ROS) generation and glutathione levels.
- Assessment of endothelial cell elasticity and F-actin cytoskeleton reorganization.
- Functional assessment of endothelium-dependent responses in mouse aortic rings.
Main Results:
- Both drugs induced DNA damage and nuclear changes at nanomolar concentrations, with differential nuclear accumulation.
- Micromolar concentrations led to increased ROS, decreased glutathione, altered endothelial elasticity, and cytoskeletal changes.
- Daunorubicin exhibited greater potency than doxorubicin in impairing endothelium-dependent responses in aortic rings.
Conclusions:
- Structurally similar anthracyclines, doxorubicin and daunorubicin, display distinct endotheliotoxic potencies.
- Differences in nuclear accumulation and DNA damage response correlate with varying endothelial toxicities.
- Findings provide insights into anthracycline-induced vascular toxicities and inform therapeutic strategies.

